Share on StockTwits

Bio Blast Pharma’s (NASDAQ:ORPN) quiet period is set to end on Tuesday, September 9th. Bio Blast Pharma had issued 3,200,000 shares in its IPO on July 31st, Analyst Ratings Network.com reports. The total size of the offering was $35,200,000 based on an initial share price of $11.00. During the company’s quiet period, insiders and underwriters involved in the IPO are restricted from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Several analysts have recently commented on the stock. Analysts at Roth Capital initiated coverage on shares of Bio Blast Pharma in a research note on Monday, August 25th. They set a “buy” rating and a $15.00 price target on the stock. Analysts at Oppenheimer initiated coverage on shares of Bio Blast Pharma in a research note on Monday, August 25th. They set an “outperform” rating and a $32.00 price target on the stock.

Bio Blast Pharma (NASDAQ:ORPN) remained flat at $8.87 during trading on Thursday. Bio Blast Pharma has a 52-week low of $6.61 and a 52-week high of $11.00. The stock’s 50-day moving average is $7.99 and its 200-day moving average is $7.99. The company’s market cap is $126.2 million.

Bio Blast Pharma (NASDAQ:ORPN) last released its earnings data on Friday, August 29th. The company reported ($0.10) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.09) by $0.01. Analysts expect that Bio Blast Pharma will post $-0.38 EPS for the current fiscal year.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.